Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Levels of New Inflammatory Markers in GDM Patients; Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

NCT04238936 is registered in ClinicalTrials.gov with Kanuni Sultan Suleyman Training and Research Hospital as lead sponsor.

NCT NCT04238936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04238936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Levels of New Inflammatory Markers in GDM Patients; Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist
Lead sponsor
Kanuni Sultan Suleyman Training and Research Hospital
Phase
Observational
Overall status
Completed
Start date
January 20, 2020
Completion date
May 20, 2020
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gestational diabetes